This amendment contains no new operational or financial data — it is purely administrative. Traders should focus on upcoming quarterly results and pipeline updates for material catalysts.
Price Chart
Executive Summary
XBiotech filed Amendment No. 1 to its 2025 10-K solely to include Part III information (directors, executive compensation, security ownership, related transactions, and audit fees) that was omitted from the original filing. No financial restatements or corrections are included. The filing reveals CEO John Simard's retirement with $17.3M severance, a widened net loss to $45.54M, and declining TSR (-41.56% cumulative since 2023).
Key Facts
- Amendment only adds Part III items (10-14); no restatement or financial revision.
- Founder/CEO John Simard retired Dec 8, 2025, receiving $17,341,326 severance plus $8,530,442 bonus in 2025.
- Net loss worsened to $45.54M in 2025 from $38.53M in 2024.
- Cumulative TSR on $100 investment fell to $58.44 (decline of 41.56%) over three years.
- Auditor remains Whitley Penn LLP; no report qualifications or going concern issues noted.
- Simard's beneficial ownership at 17.5%; all directors and officers as a group hold 20.8%.
Financial Impact
No new financial data. CEO severance of $17.3M and bonus of $8.5M disclosed, contributing to 2025 net loss of $45.54M.
Risk Factors
- Sustained net losses with no approved product revenue.
- High founder ownership concentration (17.5%) creates governance risk.
- CEO retirement and reliance on interim leadership may cause strategic uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001171843-26-002814 |
| Exhibit: ex_951298.htm | 0001171843-26-002814 |
| Exhibit: ex_951299.htm | 0001171843-26-002814 |
| Document: 0001171843-26-002814-index-headers.html | 0001171843-26-002814 |
| Document: 0001171843-26-002814-index.html | 0001171843-26-002814 |
| Document: 0001171843-26-002814.txt | 0001171843-26-002814 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.92 | awaiting T+5 | — | $1.85 (−3.65%) |
Oct 2, 2026 24d ago | DEF 14A | $2.19 $2.29 | ▼ −4.57% | ▼ −3.41% | $1.85 (+15.53%) |
Apr 29, 2026 25w ago | 10-K/A | $2.52 $2.55 | ▲ +1.19% | ▼ −1.92% | $1.85 (−26.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers